Overview:

Summary

GlobalData, the industry analysis specialist, has released its new report, “AIDS-related Kaposi’s Sarcoma (ARKS) Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global AIDS Related Kaposi’s Sarcoma Therapeutics market. The report identifies the key trends shaping and driving the global AIDS Related Kaposi’s Sarcoma Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global AIDS Related Kaposi’s Sarcoma Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the AIDS Related Kaposi’s Sarcoma Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) AIDS Related Kaposi’s Sarcoma Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries AIDS Related Kaposi’s Sarcoma Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the AIDS Related Kaposi’s Sarcoma Therapeutics therapeutics market.
- Analysis of key recent licensing and partnership agreements in AIDS Related Kaposi’s Sarcoma Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global AIDS Related Kaposi’s Sarcoma Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global AIDS Related Kaposi’s Sarcoma Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global AIDS Related Kaposi’s Sarcoma Therapeutics market landscape? – Identify, understand and capitalize."

Companies Mentioned

PTC Therapeutics, Inc.
Aphios Corporation

1 Table of contents 2
1.1 List of Tables 4
1.2 List of Figures 5
2 AIDS-related Kaposi’s Sarcoma (ARKS) Therapeutics: Introduction 6
2.1 Overview 6
2.2 Epidemiology 6
2.3 Symptoms 7
2.4 Pathogenesis of ARKS 8
2.5 Staging of ARKS 9
2.6 Diagnosis of ARKS 9
2.7 Treatment of ARKS 9
2.7.1 Local Treatment 10
2.7.2 Cytotoxic Chemotherapy 10
2.7.3 Molecular Targeted Therapy 10
2.7.4 HAART (Highly Active Antiretroviral Treatment) 10
2.8 GlobalData Pipeline Report Guidance 11
3 AIDS-related Kaposi’s Sarcoma (ARKS) Therapeutics: Market Characterization 12
3.1 ARKS Therapeutics Market Size (2005–2010) – Global 12
3.2 ARKS Therapeutics Market Forecast (2010–2017) – Global 13
3.3 ARKS Therapeutics Market Size (2005–2010) – The US 14
3.4 ARKS Therapeutics Market Forecast (2010–2017) – The US 15
3.5 ARKS Therapeutics Market Size (2005–2010) – France 16
3.6 ARKS Therapeutics Market Forecast (2010–2017) – France 17
3.7 ARKS Therapeutics Market Size (2005–2010) – Germany 18
3.8 ARKS Therapeutics Market Forecast (2010–2017) – Germany 19
3.9 ARKS Therapeutics Market Size (2005–2010) – Italy 20
3.10 ARKS Therapeutics Market Forecast (2010–2017) – Italy 21
3.11 ARKS Therapeutics Market Size (2005–2010) – Spain 22
3.12 ARKS Therapeutics Market Forecast (2010–2017) – Spain 23
3.13 ARKS Therapeutics Market Size (2005–2010) – The UK 24
3.14 ARKS Therapeutics Market Forecast (2010–2017) – The UK 25
3.15 ARKS Therapeutics Market Size (2005–2010) – Japan 26
3.16 ARKS Therapeutics Market Forecast (2010–2017) – Japan 27
3.17 Drivers and Barriers for the ARKS Therapeutics Market 28
3.17.1 Barriers for the ARKS Therapeutics Market 28
3.18 Opportunity and Unmet Need Analysis 28
3.19 Key Takeaway 29
4 AIDS-related Kaposi’s Sarcoma (ARKS) Therapeutics: Competitive Assessment 30
4.1 Overview 30
4.2 Strategic Competitor Assessment 30
4.3 Product Profiles for Major Marketed Products in the ARKS Therapeutics Market 31
4.3.1 Doxil 31
4.3.2 Daunorubicin 33
4.3.3 Paclitaxel 34
4.3.4 Panretin (alitretinoin) 35
4.4 Key Takeaway 36
5 AIDS-related Kaposi’s Sarcoma (ARKS) Therapeutics: Pipeline Assessment 37
5.1 Overview 37
5.2 Strategic Pipeline Assessment 37
5.3 ARKS Therapeutics Pipeline – Pipeline by Phases of Development 37
5.3.1 ARKS Therapeutics – Phase II Pipeline 38
5.3.2 ARKS Therapeutics – Phase I Pipeline 38
5.3.3 ARKS Therapeutics – Preclinical Pipeline 38
5.3.4 Technology Trends Analytic Framework 39
5.4 ARKS Therapeutics – Pipeline by Mechanism of Action 41
5.5 Key Takeaway 41
6 AIDS-related Kaposi’s Sarcoma (ARKS) Therapeutics: Clinical Trials Mapping 42
6.1 Clinical Trials by Country (US, EU5 and Japan) 42
6.2 Clinical Trials by Phase 43
6.3 Clinical Trials by Trial Status 44
6.4 Prominent Sponsors 45
6.5 Top Companies Participating in ARKS Therapeutics Clinical Trials 47
7 AIDS-related Kaposi’s Sarcoma (ARKS) Therapeutics: Strategic Assessment 48
7.1 ARKS Therapeutics: Implications for Future Market Competition 48
8 AIDS-related Kaposi’s Sarcoma (ARKS) Therapeutics: Future Players 49
8.1 Introduction 49
8.2 Company Profiles 50
8.2.1 PTC Therapeutics, Inc. 50
8.2.2 Aphios Corporation 51
9 AIDS-related Kaposi’s Sarcoma (ARKS) Therapeutics: Licensing and Partnership Deals 53
10 AIDS-related Kaposi’s Sarcoma (ARKS) Therapeutics: Appendix 54
10.1 Market Definitions 54
10.2 Abbreviations 54
10.3 Research Methodology 55
10.3.1 Coverage 55
10.3.2 Secondary Research 55
10.3.3 Forecasting 56
10.3.4 Primary Research 59
10.3.5 Expert Panel Validation 59
10.4 Contact Us 59
10.5 Disclaimer 59
10.6 Bibliography 60"

1.1 List of Tables
Table 1: Prevalence of Kaposi’s Sarcoma in HIV Patients, Top Seven Markets, 2010 6
Table 2: AIDS Clinical Trials Group Staging Classification for ARKS, 2011 9
Table 3: ARKS Therapeutics Market, Global, Revenue ($m), 2005–2010 12
Table 4: ARKS Therapeutics Market, Global, Forecast ($m), 2010–2017 13
Table 5: ARKS Therapeutics Market, The US, Revenue ($m), 2005–2010 14
Table 6: ARKS Therapeutics Market, The US, Forecast ($m), 2010–2017 15
Table 7: ARKS Therapeutics Market, France, Revenue ($’000), 2005–2010 16
Table 8: ARKS Therapeutics Market, France, Forecast ($’000), 2010–2017 17
Table 9: ARKS Therapeutics Market, Germany, Revenue ($’000), 2005–2010 18
Table 10: ARKS Therapeutics Market, Germany, Forecast ($’000), 2010–2017 19
Table 11: ARKS Therapeutics Market, Italy, Revenue ($’000), 2005–2010 20
Table 12: ARKS Therapeutics Market, Italy, Forecast ($’000), 2010–2017 21
Table 13: ARKS Therapeutics Market, Spain, Revenue ($’000), 2005–2010 22
Table 14: ARKS Therapeutics Market, Spain, Forecast ($’000), 2010–2017 23
Table 15: ARKS Therapeutics Market, The UK, Revenue ($’000), 2005–2010 24
Table 16: ARKS Therapeutics Market, The UK, Forecast ($’000), 2010–2017 25
Table 17: ARKS Therapeutics Market, Japan, Revenue ($’000), 2005–2010 26
Table 18: ARKS Therapeutics Market, Japan, Forecast ($’000), 2010–2017 27
Table 19: Response in Patients with Refractory AIDS-related Kaposi’s Sarcoma 32
Table 20: Panretin Clinical Study Response 36
Table 21: ARKS Therapeutics – Phase II Pipeline, 2011 38
Table 22: ARKS Therapeutics – Phase I Pipeline, 2011 38
Table 23: ARKS Therapeutics – Preclinical Pipeline, 2011 38
Table 24: ARKS Therapeutics – Clinical Trials by Country, 2011 42
Table 25: ARKS Therapeutics - Clinical Trials by Phase, 2011 43
Table 26: ARKS Therapeutics - Clinical Trials by Status, 2011 44
Table 27: ARKS Therapeutics - Prominent Sponsors, 2011 46
Table 28: ARKS Therapeutics – Companies and Institutions Participating in Clinical Trials, 2011 47
Table 29: PTC Therapeutics, Pipeline Products, 2011 50
Table 30: PTC Therapeutics, Deals, 2009-2011 51
Table 31: Aphios Corporation, Pipeline Products, 2011 52
Table 32: Aphios Corporation, Deals, 2009-2011 52
Table 33: ARKS Therapeutics, Global, Deals 53"

1.2 List of Figures
Figure 1: Etiology of KS 8
Figure 2: ARKS Therapeutics Market, Global, Revenue ($m), 2005–2010 12
Figure 3: ARKS Therapeutics Market, Global, Forecast ($m), 2010–2017 13
Figure 4: ARKS Therapeutics Market, The US, Revenue ($m), 2005–2010 14
Figure 5: ARKS Therapeutics Market, The US, Forecast ($m), 2010–2017 15
Figure 6: ARKS Therapeutics Market, France, Revenue ($’000), 2005–2010 16
Figure 7: ARKS Therapeutics Market, France, Forecast ($’000), 2010–2017 17
Figure 8: ARKS Therapeutics Market, Germany, Revenue ($’000), 2005–2010 18
Figure 9: ARKS Therapeutics Market, Germany, Forecast ($’000), 2010–2017 19
Figure 10: ARKS Therapeutics Market, Italy, Revenue ($’000), 2005–2010 20
Figure 11: ARKS Therapeutics Market, Italy, Forecast ($’000), 2010–2017 21
Figure 12: ARKS Therapeutics Market, Spain, Revenue ($’000), 2005–2010 22
Figure 13: ARKS Therapeutics Market, Spain, Forecast ($’000), 2010–2017 23
Figure 14: ARKS Therapeutics Market, The UK, Revenue ($’000), 2005–2010 24
Figure 15: ARKS Therapeutics Market, The UK, Forecast ($’000), 2010–2017 25
Figure 16: ARKS Therapeutics Market, Japan, Revenue ($’000), 2005–2010 26
Figure 17: ARKS Therapeutics Market, Japan, Forecast ($’000), 2010–2017 27
Figure 18: ARKS Therapeutics Market, Drivers and Barriers, 2010 28
Figure 19: Opportunity and Unmet Need in the ARKS Therapeutics Market, 2010 29
Figure 20: ARKS Therapeutics – Strategic Competitor Assessment, 2010 30
Figure 21: ARKS Therapeutics – Pipeline by Phase of Development, (%), 2010 37
Figure 22: ARKS Therapeutics – Technology Trends Analytic Framework, 2011 39
Figure 23: ARKS Therapeutics – Technology Trends Analytic Framework – Description, 2011 40
Figure 24: ARKS Therapeutics – Pipeline by Mechanism of Action, (%), 2011 41
Figure 25: ARKS Therapeutics – Clinical Trials by Country, 2011 42
Figure 26: ARKS Therapeutics – Clinical Trials by Phase, (%), 2011 43
Figure 27: ARKS Therapeutics - Clinical Trials by Status, (%), 2011 44
Figure 28: ARKS Therapeutics - Overall Sponsors, (%), 2011 45
Figure 29: ARKS Therapeutics - Sponsors, (%), 2011 46
Figure 30:  ARKS Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011 47
Figure 31: Implications for Future Market Competition in the ARKS Therapeutics Market, 2010 48
Figure 32: ARKS Therapeutics – Pipeline by Company, 2010 49
Figure 33: GlobalData Market Forecasting Model 58